R&D JP Morgan 2024 – Graham Heap Just over a year ago, Takeda acquired a promising immunotherapy candidate, TAK-279, from Boston-based Nimbus Therapeutics.
News Amid BIOSECURE Act speculation, WuXi AppTec sells unit WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
